AltiBio, Inc. (AltiBio) was founded in early 2017 by a team with successful experience developing and commercializing orphan therapeutics. AltiBio currently has three projects in development: ATB223, ATB224, and ATB338, with two molecules, for one rare disease.
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.